201 related articles for article (PubMed ID: 29940869)
1. Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Quiros-Roldan E; Magro P; Raffetti E; Izzo I; Borghetti A; Lombardi F; Saracino A; Maggiolo F; Castelli F;
BMC Infect Dis; 2018 Jun; 18(1):285. PubMed ID: 29940869
[TBL] [Abstract][Full Text] [Related]
2. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
3. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
4. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Marchetti G; Rusconi S; Gori A; Nozza S; Lichtner M; Antinori A; Cossarizza A; d'Arminio Monforte A;
BMC Med; 2018 May; 16(1):79. PubMed ID: 29807541
[TBL] [Abstract][Full Text] [Related]
5. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
[TBL] [Abstract][Full Text] [Related]
6. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F; Ribera E; Lagarde M; Pérez-Valero I; Palacios R; Iribarren JA; Payeras A; Domingo P; Sanz J; Cervero M; Curran A; Rodríguez-Gómez FJ; Téllez MJ; Ryan P; Barrufet P; Knobel H; Rivero A; Alejos B; Yllescas M; Arribas JR;
Clin Infect Dis; 2017 Nov; 65(12):2112-2118. PubMed ID: 29020293
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
8. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
[TBL] [Abstract][Full Text] [Related]
9. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
10. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Latini A; Fabbiani M; Borghi V; Sterrantino G; Giannetti A; Lorenzini P; Loiacono L; Ammassari A; Bellagamba R; Colafigli M; D'Ettorre G; Di Giambenedetto S; Antinori A; Zaccarelli M
BMC Infect Dis; 2016 Aug; 16(1):401. PubMed ID: 27515949
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
12. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
[TBL] [Abstract][Full Text] [Related]
13. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
16. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
17. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
18. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
Tsai MS; Chang SY; Lin SW; Kuo CH; Sun HY; Wu BR; Tang SY; Liu WC; Su YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Dec; 50(6):789-797. PubMed ID: 26857335
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy management and rationalisation of available resources.
Cirioni O; Castelletti S; Ucciferri C; Falasca K; Orsetti E; Mazzocato S; Valeriani C; Di Campli FM; Barchiesi F; Vecchiet J; Giacometti A
Infez Med; 2015 Dec; 23(4):330-5. PubMed ID: 26700083
[TBL] [Abstract][Full Text] [Related]
20. Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
Hung TC; Chen GJ; Cheng SH; Chen JH; Wei JL; Cheng CY; Hung CC
J Microbiol Immunol Infect; 2019 Dec; 52(6):865-871. PubMed ID: 31422059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
